HopeStage
Back to all studies
CompletedNCT00667121

Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline

Observational studyAges 18–120United StatesDepression
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 120 years.

Listed locations
Indianapolis and 5 more locationsSee all locations and recruitment

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: March 16, 2011
Recruitment status
Completed
Enrollment listed in the registry
88
Sponsor
Mayo Clinic
Sponsor type
Hospital / academic medical center
Study type
Observational
Intervention type
Drug, Genetic, Other, Procedure
Locations
United States
Age range
From 18 Years to 120 Years
Official registry ID
NCT00667121
Official title
Show the full official title

The Effect of Antidepressants and Gabapentin on Tamoxifen Pharmacokinetics: A Prospective Study

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Indianapolis · Baltimore · Ann Arbor

3 more locations
  • Rochester
  • Chapel Hill
  • Arlington

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Mayo Clinic, a hospital or academic medical center.

Did this study involve medication?

Yes. The study involved medication, including citalopram hydrobromide, escitalopram oxalate, gabapentin, sertraline hydrochloride, tamoxifen citrate and venlafaxine.

Who was this study for?

Listed age limits: 18 years to 120 years.

Want to explore more studies?

Explore studies